Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 7%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares rose 7% during mid-day trading on Tuesday . The company traded as high as $16.39 and last traded at $16.22. Approximately 296,275 shares were traded during trading, a decline of 26% from the average daily volume of 402,522 shares. The stock had previously closed at $15.16.

Analysts Set New Price Targets

YMAB has been the subject of a number of analyst reports. Wedbush restated an “outperform” rating and set a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a research report on Monday, February 12th. Canaccord Genuity Group lifted their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. BMO Capital Markets lifted their target price on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a report on Monday, March 4th. Finally, HC Wainwright lifted their target price on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $16.57.

Y-mAbs Therapeutics Trading Up 1.2 %

The company has a 50-day moving average of $15.78 and a 200-day moving average of $10.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. The company had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. As a group, research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the transaction, the senior vice president now owns 33,889 shares of the company’s stock, valued at $560,185.17. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at $34,000. Tower Research Capital LLC TRC raised its stake in Y-mAbs Therapeutics by 345.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock valued at $46,000 after acquiring an additional 5,185 shares during the period. Bailard Inc. purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at about $115,000. SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics during the third quarter valued at about $100,000. Finally, Exchange Traded Concepts LLC boosted its position in Y-mAbs Therapeutics by 29.4% during the third quarter. Exchange Traded Concepts LLC now owns 20,971 shares of the company’s stock worth $114,000 after purchasing an additional 4,763 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.